<p>GH Research PLC（納斯達克代碼：GHRS - 獲取免費報告）獲得了覆蓋該公司的十一家研究機構的平均推薦評級為 “適度買入”，Marketbeat Ratings 報告稱。一位投資分析師給予該股票賣出評級，一位給予持有評級，九位給予該公司買入評級。在過去一年中，發佈報告的分析師對該股票的平均 12 個月目標價為 40.1250 美元。</p>
<ul>
<li>3 只分析師認為價格將翻倍的快速增長股票</li>
</ul>
<p>幾家研究機構對 GHRS 進行了評論。Needham &amp; Company LLC 將 GH Research 的目標價格從 31.00 美元上調至 32.00 美元，並在 3 月 6 日的研究報告中給予該股票 “買入” 評級。加拿大皇家銀行將 GH Research 的目標價格從 33.00 美元上調至 40.00 美元，並在 1 月 23 日的報告中給予該股票 “跑贏大盤” 評級。Weiss Ratings 在 4 月 21 日的研究報告中重申了對 GH Research 的 “賣出（d-）” 評級。Guggenheim 在 3 月 10 日的研究報告中將 GH Research 的目標價格設定為 34.00 美元，並給予該公司 “買入” 評級。最後，Wolfe Research 在 1 月 6 日的研究報告中將 GH Research 的目標價格設定為 39.00 美元。</p>
<p><strong>閲讀我們關於 GH Research 的最新研究報告</strong></p>
<h2>機構資金流入和流出</h2>
<p>大型投資者最近調整了對該股票的持有。Lynx1 Capital Management LP 在第三季度將其在 GH Research 的持倉增加了 27.5%。Lynx1 Capital Management LP 目前擁有 8,601,189 股該公司的股票，價值 122,997,000 美元，此前在上個季度增持了 1,854,238 股。RTW Investments LP 在第四季度將其在 GH Research 的持倉增加了 6.5%。RTW Investments LP 目前擁有 5,933,815 股該公司的股票，價值 75,359,000 美元，此前在上個季度增持了 364,251 股。Avoro Capital Advisors LLC 在第四季度購買了 GH Research 的新頭寸，價值約 22,860,000 美元。Millennium Management LLC 在第三季度將其在 GH Research 的持倉增加了 324.1%。Millennium Management LLC 目前擁有 863,602 股該公司的股票，價值 12,350,000 美元，此前在此期間增持了 659,957 股。最後，Jefferies Financial Group Inc.在第四季度將其在 GH Research 的持倉增加了 0.4%。Jefferies Financial Group Inc.目前擁有 712,300 股該公司的股票，價值 9,046,000 美元，此前在上個季度增持了 2,988 股。56.90% 的股票目前由對沖基金和其他機構投資者持有。</p>
<h2>GH Research 下跌 1.9%</h2>
<p>納斯達克：GHRS 週三開盤價為 21.28 美元。GH Research 的 12 個月低點為 9.46 美元，12 個月高點為 24.66 美元。該公司的市值為 13.2 億美元，市盈率為-26.60，貝塔值為 1.27。該公司的 50 日移動平均線為 16.16 美元，200 日移動平均線為 15.08 美元。</p>
<p>GH Research（納斯達克：GHRS - 獲取免費報告）在 3 月 6 日最後發佈了季度財報。該公司報告季度每股收益（EPS）為（0.23）美元，超出分析師共識預期的（0.29）美元 0.06 美元。平均而言，股票研究分析師預測 GH Research 在當前財年將發佈-1.52 美元的每股收益。</p>
<h2>GH Research 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>GH Research Holdings Inc 是一家臨牀階段的生物技術公司，致力於通過應用靈感來自迷幻藥的化合物開發新型神經精神疾病治療方案。公司總部位於愛爾蘭都柏林，專注於利用 5-美氧基-N-二甲基色胺（5-MeO-DMT）及相關分子的獨特藥理學，以滿足心理健康領域的重大未滿足醫療需求。</p>
<p>該公司的主導項目 GH001 是一種吸入式 5-MeO-DMT 製劑，已完成早期臨牀試驗，評估其在難治性抑鬱症中的安全性、耐受性和初步療效。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 GH Research</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0hSUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0hSUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 GH Research 嗎？</h2>
<p>在考慮 GH Research 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 GH Research 並不在名單上。</p>
<p>雖然 GH Research 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

GHRS

基因改革 ETF - ARK

醫療業 ETF - Vanguard

<p>GH Research PLC（納斯達克代碼：GHRS）獲得了來自十一家研究公司的 “適度買入” 平均評級。一位分析師將其評為賣出，一位評為持有，九位評為買入。12 個月的平均目標價為 40.13 美元。顯著的目標價上調包括 Needham 將其上調至 32 美元，皇家銀行將其上調至 40 美元。該股票目前交易價格為 21.28 美元，市值為 13.2 億美元。GH Research 專注於開發用於治療神經精神疾病的靈感來源於迷幻藥的化合物</p>

<p>GH Research PLC (NASDAQ:GHRS - Get Free Report) has received an average recommendation of &#34;Moderate Buy&#34; from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $40.1250.</p>
<div class="lb-trans"><p>GH Research PLC（納斯達克代碼：GHRS - 獲取免費報告）獲得了覆蓋該公司的十一家研究機構的平均推薦評級為 “適度買入”，Marketbeat Ratings 報告稱。一位投資分析師給予該股票賣出評級，一位給予持有評級，九位給予該公司買入評級。在過去一年中，發佈報告的分析師對該股票的平均 12 個月目標價為 40.1250 美元。</p>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只分析師認為價格將翻倍的快速增長股票</li>
</ul>
</div><p>Several research firms have commented on GHRS. Needham &amp; Company LLC lifted their target price on shares of GH Research from $31.00 to $32.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, March 6th. Royal Bank Of Canada raised their price objective on GH Research from $33.00 to $40.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, January 23rd. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of GH Research in a research report on Tuesday, April 21st. Guggenheim set a $34.00 target price on GH Research and gave the company a &#34;buy&#34; rating in a research note on Tuesday, March 10th. Finally, Wolfe Research set a $39.00 target price on GH Research in a research report on Tuesday, January 6th.</p>
<div class="lb-trans"><p>幾家研究機構對 GHRS 進行了評論。Needham &amp; Company LLC 將 GH Research 的目標價格從 31.00 美元上調至 32.00 美元，並在 3 月 6 日的研究報告中給予該股票 “買入” 評級。加拿大皇家銀行將 GH Research 的目標價格從 33.00 美元上調至 40.00 美元，並在 1 月 23 日的報告中給予該股票 “跑贏大盤” 評級。Weiss Ratings 在 4 月 21 日的研究報告中重申了對 GH Research 的 “賣出（d-）” 評級。Guggenheim 在 3 月 10 日的研究報告中將 GH Research 的目標價格設定為 34.00 美元，並給予該公司 “買入” 評級。最後，Wolfe Research 在 1 月 6 日的研究報告中將 GH Research 的目標價格設定為 39.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on GH Research</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 GH Research 的最新研究報告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Large investors have recently modified their holdings of the stock. Lynx1 Capital Management LP boosted its position in shares of GH Research by 27.5% in the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company's stock worth $122,997,000 after acquiring an additional 1,854,238 shares during the last quarter. RTW Investments LP increased its position in GH Research by 6.5% during the fourth quarter. RTW Investments LP now owns 5,933,815 shares of the company's stock worth $75,359,000 after purchasing an additional 364,251 shares during the last quarter. Avoro Capital Advisors LLC purchased a new position in GH Research during the fourth quarter worth approximately $22,860,000. Millennium Management LLC raised its stake in GH Research by 324.1% during the third quarter. Millennium Management LLC now owns 863,602 shares of the company's stock worth $12,350,000 after purchasing an additional 659,957 shares during the period. Finally, Jefferies Financial Group Inc. boosted its holdings in shares of GH Research by 0.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 712,300 shares of the company's stock valued at $9,046,000 after purchasing an additional 2,988 shares during the last quarter. 56.90% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投資者最近調整了對該股票的持有。Lynx1 Capital Management LP 在第三季度將其在 GH Research 的持倉增加了 27.5%。Lynx1 Capital Management LP 目前擁有 8,601,189 股該公司的股票，價值 122,997,000 美元，此前在上個季度增持了 1,854,238 股。RTW Investments LP 在第四季度將其在 GH Research 的持倉增加了 6.5%。RTW Investments LP 目前擁有 5,933,815 股該公司的股票，價值 75,359,000 美元，此前在上個季度增持了 364,251 股。Avoro Capital Advisors LLC 在第四季度購買了 GH Research 的新頭寸，價值約 22,860,000 美元。Millennium Management LLC 在第三季度將其在 GH Research 的持倉增加了 324.1%。Millennium Management LLC 目前擁有 863,602 股該公司的股票，價值 12,350,000 美元，此前在此期間增持了 659,957 股。最後，Jefferies Financial Group Inc.在第四季度將其在 GH Research 的持倉增加了 0.4%。Jefferies Financial Group Inc.目前擁有 712,300 股該公司的股票，價值 9,046,000 美元，此前在上個季度增持了 2,988 股。56.90% 的股票目前由對沖基金和其他機構投資者持有。</p>
</div><h2>GH Research Trading Down 1.9%</h2>
<div class="lb-trans"><h2>GH Research 下跌 1.9%</h2>
</div><p>NASDAQ:GHRS opened at $21.28 on Wednesday. GH Research has a 12-month low of $9.46 and a 12-month high of $24.66. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -26.60 and a beta of 1.27. The company's 50-day moving average is $16.16 and its two-hundred day moving average is $15.08.</p>
<div class="lb-trans"><p>納斯達克：GHRS 週三開盤價為 21.28 美元。GH Research 的 12 個月低點為 9.46 美元，12 個月高點為 24.66 美元。該公司的市值為 13.2 億美元，市盈率為-26.60，貝塔值為 1.27。該公司的 50 日移動平均線為 16.16 美元，200 日移動平均線為 15.08 美元。</p>
</div><p>GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Friday, March 6th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.06. On average, equities research analysts forecast that GH Research will post -1.52 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>GH Research（納斯達克：GHRS - 獲取免費報告）在 3 月 6 日最後發佈了季度財報。該公司報告季度每股收益（EPS）為（0.23）美元，超出分析師共識預期的（0.29）美元 0.06 美元。平均而言，股票研究分析師預測 GH Research 在當前財年將發佈-1.52 美元的每股收益。</p>
</div><h2>GH Research Company Profile</h2>
<div class="lb-trans"><h2>GH Research 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.</p>
<div class="lb-trans"><p>GH Research Holdings Inc 是一家臨牀階段的生物技術公司，致力於通過應用靈感來自迷幻藥的化合物開發新型神經精神疾病治療方案。公司總部位於愛爾蘭都柏林，專注於利用 5-美氧基-N-二甲基色胺（5-MeO-DMT）及相關分子的獨特藥理學，以滿足心理健康領域的重大未滿足醫療需求。</p>
</div><p>The firm's lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.</p>
<div class="lb-trans"><p>該公司的主導項目 GH001 是一種吸入式 5-MeO-DMT 製劑，已完成早期臨牀試驗，評估其在難治性抑鬱症中的安全性、耐受性和初步療效。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than GH Research</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 GH Research</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0hSUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=GHRS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GH Research Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 GH Research 嗎？</h2>
</div><p>Before you consider GH Research, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 GH Research 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 GH Research 並不在名單上。</p>
</div><p>While GH Research currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 GH Research 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Brokerages

Market Beat

GH Research

標普生物技術 3 倍做多 - Direxion

標普全球醫療股指數 ETF - iShares

納斯達克生物科技指數 ETF - iShares Nasdaq

動態生物技術與基因組 ETF - Invesco

醫療業 ETF - SPDR

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

標普生物技術 ETF - SPDR

加拿大皇家銀行

禧圖集團

Jefferies Financial

GH Research PLC（NASDAQ:GHRS）被券商給予 “適度買入” 的平均評級